PEIJIA-B(09996): The registration application for the Shenpuchang SeQuent Please CIS paclitaxel drug-coated intracranial balloon dilation catheter has been approved by the National Medical Products Administration.

PEIJIA-B (09996) announced that the registration application for the Shenpuchang SeQuent Please CIS paclitaxel drug-coated intracranial balloon dilation catheter ("SeQuent Please CIS" or "the Product") has recently been approved by the National Medical Products Administration of China. SeQuent Please CIS is registered by B. Braun Medical (Suzhou) Co., Ltd. (B. Braun Medical) and is an intracranial paclitaxel drug-coated balloon dilation catheter developed based on B. Braun Medical's mature drug-coated balloon technology. During mechanical dilation of the target lesion, the product precisely releases the coated paclitaxel to the diseased vessel wall. As an anti-proliferative drug, it effectively inhibits intimal hyperplasia and reduces the long-term risk of restenosis. The product is specifically designed for the slender and tortuous anatomical characteristics of intracranial vessels, aiming to provide an innovative "implant-free" treatment option for intracranial vascular diseases. The Company's subsidiary, Shanghai Jiaqi Biotechnology Suzhou Co., Ltd., has obtained the exclusive distribution rights for SeQuent Please CIS in mainland China. The approval of SeQuent Please CIS by the National Medical Products Administration further expands the Group's neurointerventional product portfolio and consolidates the Group's product layout in the field of intracranial atherosclerotic stenosis treatment. The Group will leverage its established commercialization capabilities in the neurointerventional field to support the market introduction and commercialization process of SeQuent Please CIS in mainland China.